Korea Reimburses Zolgensma Amid Wider Cost Management Initiatives
Zolgensma becomes the second Novartis gene therapy - and highest-priced therapeutic product - to be reimbursed in South Korea, prompting authorities to come up with plans to manage expensive therapies to ensure the sustainability of the national health insurance system.
You may also be interested in...
An initiative that will improve payers’ ability to negotiate prices for disruptive new drugs is closer to fruition.
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback
Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.